Evidence map›Paper›PMID 40481348›Full record

ArticleCommunications medicine2025

MicroRNA-15a-5p mediates abdominal aortic aneurysm progression and serves as a potential diagnostic and prognostic circulating biomarker.

Greg Winski, Ekaterina Chernogubova, Albert Busch, Suzanne M Eken, Hong Jin, Moritz Lindquist Liljeqvist, Tooba Khan, Alexandra Bäcklund, Valentina Paloschi, Joy Roy and 11 more

Abstract read
In one paragraph

Article in Communications medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Greg WinskiDepartment of Medicine, Solna, Karolinska Institutet, Stockholm, Sweden.ORCID http://orcid.org/0000-0002-1832-5423
Ekaterina ChernogubovaDepartment of Medicine, Solna, Karolinska Institutet, Stockholm, Sweden.
Albert BuschDivision of Vascular and Endovascular Surgery, Department for Visceral-, Thoracic and Vascular Surgery, Medical Faculty Carl Gustav Carus and University Hospital, Technische Universität Dresden, Dresden, Germany.
Suzanne M EkenDepartment of Medicine, Solna, Karolinska Institutet, Stockholm, Sweden.
Hong JinDepartment of Medicine, Solna, Karolinska Institutet, Stockholm, Sweden.
Moritz Lindquist LiljeqvistDepartment of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden.
Tooba KhanVeterans Affairs Palo Alto Health Care System, Palo Alto, CA, USA.
Alexandra BäcklundDepartment of Medicine, Solna, Karolinska Institutet, Stockholm, Sweden.
Valentina PaloschiDepartment for Vascular and Endovascular Surgery, Klinikum Rechts der Isar, Technical University of Munich, Munich, Germany.
Joy RoyDepartment of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden.
Rebecka HultgrenDepartment of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden.
Christine BrostjanDivision of Vascular Surgery, Department of General Surgery, Medical University of Vienna, Vienna, Austria.
Gert J de BorstDepartment of Vascular Surgery, University Medical Center Utrecht, Utrecht, The Netherlands.
Joost P G SluijterDepartment of Cardiology, Experimental Cardiology Laboratory, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.ORCID http://orcid.org/0000-0003-2088-9102
Nadja SachsDepartment for Vascular and Endovascular Surgery, Klinikum Rechts der Isar, Technical University of Munich, Munich, Germany.ORCID http://orcid.org/0000-0001-8031-017X
Hans-Henning EcksteinDepartment for Vascular and Endovascular Surgery, Klinikum Rechts der Isar, Technical University of Munich, Munich, Germany.
Reinier A BoonDepartment of Physiology, VU University Medical Center in Amsterdam, Amsterdam, The Netherlands.ORCID http://orcid.org/0000-0001-7944-9748
Joshua M SpinVeterans Affairs Palo Alto Health Care System, Palo Alto, CA, USA.ORCID http://orcid.org/0000-0002-4256-9161
Philip S TsaoVeterans Affairs Palo Alto Health Care System, Palo Alto, CA, USA.
Folkert W AsselbergsDepartment of Cardiology, Amsterdam Cardiovascular Sciences, Amsterdam University Medical Centre, University of Amsterdam, Amsterdam, The Netherlands.
Lars MaegdefesselDepartment of Medicine, Solna, Karolinska Institutet, Stockholm, Sweden. lars.maegdefessel@tum.de.

Funding

Deutsche Forschungsgemeinschaft (German Research Foundation) SFB1123Deutsche Forschungsgemeinschaft (German Research Foundation) TRR267EC | EU Framework Programme for Research and Innovation H2020 | H2020 Priority Excellent Science | H2020 European Research Council (H2020 Excellent Science - European Research Council) ERC-StG NORVASVetenskapsrådet (Swedish Research Council) 2019-01577
6 · The paper itself

Abstract

backgroundMicroRNAs are post transcriptional modulators of gene expression. We explored the diagnostic and prognostic value of circulating microRNAs in abdominal aortic aneurysm (AAA) disease, for which currently no established circulating biomarker is available.

methodsWe profiled the expression of 754 human microRNAs in plasma from 187 patients with AAA and 190 matched non-diseased controls. To validate, we used two additional AAA patient cohorts, looking at circulating and aortic tissue-derived microRNA expression, and their correlation to AAA disease phenotype, as well as two murine AAA models.

resultsWe show that among 12 differentially expressed microRNAs, miR-15a and -659 are the most significantly up-regulated in AAA, whereas miR-1183 and -192 are the most significantly down-regulated. miR-15a is upregulated AAA patient tissues, and in plasma from two murine AAA models. In patients from three different cohorts, miR-15a expression levels in plasma, serum and aortic tunica media are significantly correlated with AAA diameter. Through modulation of miR-15a in human aortic smooth muscle cells, we identify several potential target genes of miR-15a known to be down-regulated in human AAA, suggesting its potential involvement in AAA pathology. Inhibition of miR-15a in vivo demonstrates a significant inhibition of murine aortic diameter growth at day 7.

conclusionsOur findings suggest that miR-15a is a potential biomarker of AAA. Through in vivo studies and based on its target profile, we show that miR-15a is involved in AAA pathogenesis and could help treatment, but also assist in risk-stratification of AAA patients and identify candidates for early AAA repair.

Identifiers

PMID40481348
PMCPMC12144292

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.